Skip to main content
CURE logo

Direxion Daily Healthcare Bull 3X ETF (CURE) Fund Overview

Educational signal · not a buy or sell recommendation · How to read this

$124.02 -$0.02 (-0.02%)
Vol: 27.1K|

Beta 1.58: the stock has moved about 58% more than the S&P 500.

Data from FMP · Methodology

For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR

Quick Answer

Direxion Daily Healthcare Bull 3X ETF (CURE) trades at $124.02. Direxion Daily Healthcare Bull 3X ETF (CURE) aims to provide 300% of the daily performance of the Health Care Select Sector Index. Sector: Financials.

Price as of · Last analyzed: Mar 18, 2026
Direxion Daily Healthcare Bull 3X ETF (CURE) aims to provide 300% of the daily performance of the Health Care Select Sector Index. It operates within the financial services sector, focusing on asset management for healthcare investments.

Analyst Coverage for CURE: CURE does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.

▶ Watch the CURE film Every key number, told as a short cinematic story — just press play. ~2 min

Direxion Daily Healthcare Bull 3X ETF (CURE) Financial Services Profile

IPO Year2011

Direxion Daily Healthcare Bull 3X ETF (CURE) is a leveraged exchange-traded fund designed to amplify the daily returns of the Health Care Select Sector Index, catering to investors seeking high-risk, high-reward exposure in the healthcare sector.

Data Provenance | Financial Data Quantitative Analysis Analysis: Mar 18, 2026

What Is the Investment Thesis for CURE?

AI-written as of Mar 18, 2026 — figures and tone reflect the data available then, not today's score.

The investment thesis for Direxion Daily Healthcare Bull 3X ETF (CURE) hinges on its ability to provide leveraged exposure to the healthcare sector, which has shown resilience and growth potential. With a market cap of $0.16 billion and a beta of 1.58, CURE is positioned to attract investors looking for high-risk, high-reward opportunities. The healthcare sector is projected to continue growing, driven by demographic trends such as an aging population and increased healthcare spending. Additionally, the ETF's structure allows for potential outsized returns during bullish market conditions, making it a noteworthy option for traders. However, investors must be aware of the inherent risks associated with leveraged ETFs, including the potential for significant losses in volatile markets. The absence of dividends further emphasizes the fund's focus on capital appreciation rather than income generation. Overall, CURE's performance will be closely linked to the movements of the Health Care Select Sector Index, making it essential for investors to monitor sector trends and market conditions.

Based on FMP financials and quantitative analysis

CURE Key Highlights

AI-written as of Mar 18, 2026 — figures and tone reflect the data available then, not today's score.

Market capitalization of $0.16 billion indicates a small-cap profile, appealing to niche investors.

  • Beta of 1.58 suggests higher volatility compared to the broader market, attracting risk-tolerant investors.
  • Seeks to achieve 300% of the daily performance of the Health Care Select Sector Index, offering leveraged exposure.
  • No dividend yield, focusing entirely on capital appreciation.
  • Part of a growing trend of leveraged ETFs that cater to active traders.

Who Are CURE's Competitors?

CURE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap MoonshotScore
APRW AllianzIM U.S. Equity Buffer20 Apr ETF $37.93 +0.21% $202M —
BJUN Innovator U.S. Equity Buffer ETF $49.89 +0.52% $189M —
CNRG State Street SPDR S&P Kensho Clean Power ETF $85.33 +2.18% $158M —
OALC OneAscent Large Cap Core ETF $41.56 +0.73% $249M —
OCTW AllianzIM U.S. Equity Buffer20 Oct ETF $42.16 +0.27% $327M —
BLK BlackRock, Inc. $1059.63 -0.44% $164B 49 5-pillar
BX Blackstone Inc. $111.74 -0.45% $135B 67 5-pillar
APOS Apollo Global Management, Inc. $25.59 -0.23% $74.8B 55 5-pillar

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CURE's Key Strengths?

Strong potential for high returns due to leveraged exposure.

  • Established brand recognition in the leveraged ETF market.
  • Focus on a resilient and growing sector, healthcare.
  • No dividend payouts, allowing for reinvestment of returns.

What Are CURE's Weaknesses?

High volatility may deter conservative investors.

  • Not suitable for long-term investment strategies.
  • Absence of dividends limits appeal to income-focused investors.
  • Performance can deviate significantly from the index over time.

What Are the Key Risks for CURE?

High volatility may lead to significant losses for investors.

  • Regulatory risks that could impact the healthcare sector.
  • Competition from other leveraged ETFs could affect performance.
  • Economic downturns may reduce overall healthcare spending.
  • Deviations from the index performance due to compounding effects.

What Are CURE's Competitive Advantages?

  • CURE's leveraged structure allows for potentially higher returns compared to traditional ETFs.
  • The fund's focus on the healthcare sector capitalizes on a growing and resilient industry.
  • Direxion's established reputation in the leveraged ETF space provides credibility and trust.
  • The ETF's unique investment strategy attracts a specific segment of risk-tolerant investors.
  • CURE's absence of dividends aligns with the needs of active traders focused on capital gains.

What Does CURE Do?

The Direxion Daily Healthcare Bull 3X ETF (CURE) was launched to provide investors with a vehicle to gain leveraged exposure to the healthcare sector. This exchange-traded fund (ETF) seeks to deliver daily investment results that correspond to 300% of the performance of the Health Care Select Sector Index, before fees and expenses. The fund is designed for short-term trading and is not intended for long-term investment due to the compounding effects of leverage, which can lead to significant deviations from the index performance over extended periods. CURE is part of Direxion's suite of leveraged ETFs, which aim to meet the demands of active traders and investors looking to capitalize on short-term market movements. The ETF does not pay dividends, which aligns with its strategy of reinvesting returns to maximize growth potential in a volatile market. As of now, CURE has a market capitalization of approximately $0.16 billion and a beta of 1.58, indicating higher volatility compared to the broader market. The fund's performance is closely tied to the dynamics of the healthcare sector, which includes pharmaceuticals, biotechnology, medical devices, and healthcare providers. Investors are attracted to CURE for its potential to amplify returns in a sector that is often seen as resilient and growth-oriented.

What Products and Services Does CURE Offer?

  • CURE is an exchange-traded fund (ETF) that seeks to provide 300% of the daily performance of the Health Care Select Sector Index.
  • The fund is designed for short-term trading and is not suitable for long-term investment strategies.
  • CURE does not pay dividends, focusing solely on capital appreciation.
  • It offers investors leveraged exposure to the healthcare sector, which includes pharmaceuticals, biotechnology, and healthcare providers.
  • The ETF is actively managed to track the performance of its underlying index closely.
  • CURE is part of a broader suite of leveraged ETFs offered by Direxion.

How Does CURE Make Money?

  • CURE generates revenue through management fees associated with its ETF structure.
  • The fund's performance is linked to the Health Care Select Sector Index, allowing for leveraged returns.
  • CURE does not distribute dividends, opting to reinvest returns for growth.
  • The ETF's strategy is designed to attract active traders looking for short-term gains in the healthcare sector.
  • Management focuses on maintaining the fund's objectives while navigating market volatility.

What Industry Does CURE Operate In?

The asset management industry, particularly in the realm of ETFs, has seen significant growth over the past decade, with increasing investor interest in specialized sectors such as healthcare. The healthcare sector is projected to grow steadily, driven by factors such as technological advancements, an aging population, and rising healthcare expenditures. CURE fits into this landscape as a leveraged ETF that allows investors to capitalize on the potential upside of the healthcare sector while also exposing them to higher risks. The competitive landscape includes various other leveraged ETFs such as APRW, BJUN, CNRG, OALC, and OCTW, each targeting different aspects of the healthcare and broader financial markets.

Who Are CURE's Key Customers?

  • Active traders seeking leveraged exposure to the healthcare sector.
  • Institutional investors looking for short-term investment strategies.
  • Retail investors interested in capital appreciation rather than income generation.
  • Hedge funds and other investment vehicles that utilize leveraged ETFs for tactical asset allocation.
  • Investors who are bullish on the healthcare sector and willing to accept higher risk.
Model self-rating on this text: 71% (not a measure of the evidence) Updated: Mar 18, 2026

Research confidence

Low

Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.

  • ● Scoring coverage unknown
  • ● Price is current
  • ● No filing on record
  • ● No analyst coverage
  • ● This is an etf, not an operating company

MoonshotScore History

Recorded daily since 2026-08-23 · 42 snapshots

2026-08-23 47
2026-08-31 47
2026-09-08 47
2026-09-16 47
2026-09-24 47
2026-10-04 47
2026-10-05 47

What changed?

The score has stayed at 47.

Over the same 30 days the stock moved -9.1%.

Net selling

Insider Activity

12 transactions · 0 purchases, 11 sales, 1 other transactions · 3 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

CURE Financials

Bull Case vs Bear Case

Bull Case

  • Strong potential for high returns due to leveraged exposure.
  • Established brand recognition in the leveraged ETF market.
  • Focus on a resilient and growing sector, healthcare.
  • No dividend payouts, allowing for reinvestment of returns.

Bear Case

  • High volatility may deter conservative investors.
  • Not suitable for long-term investment strategies.
  • Absence of dividends limits appeal to income-focused investors.
  • Performance can deviate significantly from the index over time.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026

CURE Latest News

CURE Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for CURE.

Price Targets

Wall Street price target analysis for CURE.

CURE MoonshotScore

MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for CURE; grades run from A+ (80-100) to F (below 30).

What Investors Ask About Direxion Daily Healthcare Bull 3X ETF (CURE) — Financials

What does Direxion Daily Healthcare Bull 3X ETF do?

The Direxion Daily Healthcare Bull 3X ETF (CURE) is designed to provide investors with 300% of the daily performance of the Health Care Select Sector Index.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated

MoonshotScore is not published for this security.

Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • The analysis is based on current market conditions and available data. Future performance may vary significantly.
Data Sources
Financial Modeling Prep (FMP)Stock Expert AI proprietary analysis